These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31877464)

  • 1. Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study.
    Li X; Lu J; Zhang L; Luo Y; Zhao Z; Li M
    Transl Oncol; 2020 Feb; 13(2):321-328. PubMed ID: 31877464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
    BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Omoto Y; Iwase H
    Transl Oncol; 2017 Oct; 10(5):766-771. PubMed ID: 28778025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis.
    Urso L; Vernaci G; Carlet J; Lo Mele M; Fassan M; Zulato E; Faggioni G; Menichetti A; Di Liso E; Griguolo G; Falci C; Conte P; Indraccolo S; Guarneri V; Dieci MV
    Front Oncol; 2021; 11():625636. PubMed ID: 33777770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
    Gyanchandani R; Kota KJ; Jonnalagadda AR; Minteer T; Knapick BA; Oesterreich S; Brufsky AM; Lee AV; Puhalla SL
    Oncotarget; 2017 Sep; 8(40):66901-66911. PubMed ID: 28978004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
    Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
    JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Stergiopoulou D; Markou A; Tzanikou E; Ladas I; Makrigiorgos GM; Georgoulias V; Lianidou E
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
    Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
    Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Transl Res; 2015 Dec; 166(6):540-553.e2. PubMed ID: 26434753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
    Drouyer A; Beaussire L; Jorda P; Leheurteur M; Guillemet C; Berghian A; Georgescu D; Di Fiore F; Perdrix A; Clatot F
    BMC Cancer; 2023 Nov; 23(1):1061. PubMed ID: 37924026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of circulating
    Zhang K; Hong R; Xu F; Xia W; Kaping L; Qin G; Zheng Q; Lu Q; Shi YX; Yuan ZY; Wang S
    Cancer Manag Res; 2018; 10():2573-2580. PubMed ID: 30147360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
    Sundaresan TK; Dubash TD; Zheng Z; Bardia A; Wittner BS; Aceto N; Silva EJ; Fox DB; Liebers M; Kapur R; Iafrate J; Toner M; Maheswaran S; Haber DA
    Breast Cancer Res Treat; 2021 Jul; 188(1):43-52. PubMed ID: 34101078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
    Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
    Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
    Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
    Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single droplet digital PCR for ESR1 activating mutations detection in plasma.
    Jeannot E; Darrigues L; Michel M; Stern MH; Pierga JY; Rampanou A; Melaabi S; Benoist C; Bièche I; Vincent-Salomon A; El Ayachy R; Noret A; Epaillard N; Cabel L; Bidard FC; Proudhon C
    Oncogene; 2020 Apr; 39(14):2987-2995. PubMed ID: 32042112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer.
    Zhu W; Ren C; Wang Y; Wen L; Zhang G; Liao N
    Onco Targets Ther; 2020; 13():615-621. PubMed ID: 32021303
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

  • 20. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
    Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
    Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.